Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted toxins.

A E Frankel1, R J Kreitman, E A Sausville

  • 1Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. AFrankel@WFUBMC.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 26, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Oncogene·2017
Same author

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Bone marrow transplantation·2016
Same author

12 making fusion toxins to target leukemia and lymphoma.

Methods in molecular medicine·2011
Same author

Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.

Current drug targets·2009
Same author

Autophagy regulates selective HMGB1 release in tumor cells that are destined to die.

Cell death and differentiation·2008
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Targeted toxins, a novel cancer therapy, combine tumor-targeting molecules with toxins to kill cancer cells by halting protein synthesis and triggering apoptosis. Clinical studies show promise, but further research is needed to overcome pharmacological challenges.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted toxins represent a novel therapeutic strategy in cancer treatment.
  • These agents comprise tumor-selective ligands conjugated to potent polypeptide toxins.

Purpose of the Study:

  • To discuss the development and clinical application of targeted toxins.
  • To review the mechanisms of action, promising results, and challenges associated with this therapeutic class.

Main Methods:

  • Production of targeted toxins under good manufacturing practice (GMP) conditions.
  • Systemic administration of these agents to patients with various neoplasms.

Main Results:

  • Targeted toxins demonstrate efficacy by inactivating cytosolic protein synthesis.

Related Experiment Videos

  • Induction of apoptosis in malignant cells is a key mechanism.
  • Early clinical studies in patients with diverse cancers show promising outcomes.

    • Conclusions:

    • Targeted toxins are a promising new class of cancer therapeutics.
    • Further pharmacological research is essential to address existing hurdles for broader clinical application.